中國生物製藥(01177.HK)標普ESG評分再獲提升蟬聯全球前9%
格隆匯12月11日丨中國生物製藥(01177.HK)公吿,根據標普全球企業可持續發展評估(S&P Global Corporate Sustainability Assessment,CSA)公佈的2023年環境、社會及管治(ESG)評分結果,中國生物製藥實現連續第二年評分提升,本年度評分穩步提升至55分,較上一年度提升10分,蟬聯全球前9%。
在公司治理方面,中國生物製藥持續提升董事會專業性、獨立性及多元化水平,以高質量公司治理保障企業穩定運行。近年來,中國生物製藥堅持國際化創新,持續加大自主研發投入力度。目前,集團進入創新成果收穫期。2022年,創新藥淨收入達67.5億元,同比增長20%。未來三年,集團將有近10款創新藥上市,為長期可持續發展注入強大動力。在風險管理領域,集團充分考量並防控ESG、新興風險等領域,並積極打造陽光誠信的企業文化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.